Novelix Pharmaceuticals Ltd, formerly Trimurthi Limited, is an India-based company, which is engaged in the business of trading pharmaceuticals and related products and is in the business of trading shares and securities. The Company's segments include Pharma Business, Investment is Shares, Trading in shares, Foods, and Finance.

Employees

Sector

Investment Banking & Brokerage Services

More about the company

Quotes

Date	Price	Change	Volume
18/09/26	₹78.26	+0.13%	1,901
17/09/26	₹78.16	-1.70%	800
16/09/26	₹79.51	-0.46%	11,761
15/09/26	₹79.88	+3.07%	8,114
11/09/26	₹77.50	+3.32%	926

Delayed Quote Bombay S.E.

More quotes

Market Closed - Bombay S.E. 14:02:28 18/09/2026 +04			5-day change	1st Jan Change
78.26 ^INR	+0.13%		+0.98%	+24.98%

08-13	Novelix Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2026	CI
07-09	Novelix Pharmaceuticals Limited announced that it has received INR 68.4 million in funding	CI

Market Cap	2.23B 23.22M 20.25M 19.12M 17.36M 32.53M 32.66M 229M 88.37M 1.13B 87.23M 85.29M 3.64B	P/E 2025	296x	P/E 2026	46x
Enterprise Value	2.2B 22.91M 19.98M 18.86M 17.13M 32.1M 32.23M 226M 87.2M 1.12B 86.07M 84.16M 3.6B	EV / Sales 2025	0.84x	EV / Sales 2026	0.82x
Free-Float	24.95%	Yield 2025 *	-	Yield 2026	-

08-13	Novelix Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2026	CI
07-09	Novelix Pharmaceuticals Limited announced that it has received INR 68.4 million in funding	CI
06-04	Novelix Pharmaceuticals Limited announced that it expects to receive INR 68.4 million in funding	CI
05-29	Novelix Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended March 31, 2026	CI
03-30	Novelix Pharmaceuticals Limited Announces Resignation of Jivamohan Divakar Valluri as Non-Executive Director and Changes in Committee Composition, Effective March 30, 2026	CI
02-12	Novelix Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025	CI
02-12	Novelix Pharmaceuticals Limited announced that it has received INR 139.2 million in funding	CI
01-10	Novelix Pharmaceuticals Limited Confirms Appointment of Sridevi Belide as Non-Executive Non-Independent Director	CI
12-11	Novelix Pharmaceuticals Limited announced that it expects to receive INR 150 million in funding	CI
11-13	Novelix Pharmaceuticals Limited Announces Board and Committee Changes, Effective 13 November, 2025	CI
23/10/25	Novelix Pharmaceuticals Limited Appoints Sridevi Belide as an Additional Director (Non-Executive Non-Independent), Effective October 23, 2025	CI
23/10/25	Novelix Pharmaceuticals Limited announced that it expects to receive INR 33.22 million in funding from Srinidhi Fine-Chemicals LLP	CI
17/10/25	Novelix Pharmaceuticals signs agreement with GMBU E.V., Halle for astaxanthin	RE

1 day	+0.13%
1 week	+0.98%
Current month	-5.14%
1 month	+2.76%
3 months	-1.94%
6 months	+44.02%
Current year	+24.98%

Novelix Pharmaceuticals Limited Stock

Stocks

TRIMURTHI6

INE314I01036

Investment Banking & Brokerage Services

Valuation: Novelix Pharmaceuticals Limited

Chart: Novelix Pharmaceuticals Limited

Latest news: Novelix Pharmaceuticals Limited

Quotes and Performance

Price Extremes

Managers and Directors: Novelix Pharmaceuticals Limited

Other Investment Banking & Brokerage Services

Financials

Company Profile

Quotes

1 week	73.7	81.99
1 month	71.6	83.99
Current year	49.01	92
1 year	38	92
3 years	8	92
5 years	5.38	92
10 years	1.85	92

Manager	Title	Age	Since
Bhoomika Choudhary DFI	Director of Finance/CFO	-	12/02/2025
Nishita Kalantri CMP	Compliance Officer	-	01/04/2019

Director	Title	Age	Since
Venkateshwarlu Pulluru BRD	Director/Board Member	-	02/09/2024
Janardhan Das Kabra BRD	Director/Board Member	-	02/09/2024
Lakshman Samala BRD	Director/Board Member	-	12/02/2025

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NOVELIX PHARMACEUTICALS LIMITED	+0.13%	+0.98%	+100.62%	+716.06%	23.22M
MORGAN STANLEY	-0.46%	-5.50%	+27.22%	+128.36%	318B
THE GOLDMAN SACHS GROUP, INC.	-1.00%	-8.47%	+17.12%	+174.38%	285B
CITIGROUP INC.	-0.70%	-5.08%	+28.67%	+209.03%	221B
CHARLES SCHWAB	+0.59%	-1.86%	+12.83%	+81.90%	182B
CITIC SECURITIES COMPANY LIMITED	+1.45%	-1.41%	-6.38%	+19.87%	59.13B
YUANTA FINANCIAL HOLDING CO., LTD.	+1.45%	0.00%	+110.40%	+201.12%	30.49B
NOMURA HOLDINGS, INC.	-0.60%	-5.02%	+44.19%	+144.40%	29.44B
LPL FINANCIAL HOLDINGS INC.	-0.56%	-7.26%	-3.32%	+33.10%	25.83B
CSC FINANCIAL CO., LTD.	+2.86%	-0.09%	-15.23%	+43.11%	24.75B
Average	+0.37%	-3.37%	+31.61%	+175.13%	117.61B
Weighted average by Cap.	-0.17%	-5.11%	+22.14%	+140.45%

	2025	2026
Net sales	307M 3.2M 2.79M 2.64M 2.39M 4.49M 4.51M 31.59M 12.19M 156M 12.03M 11.76M 503M	1.32B 13.79M 12.03M 11.36M 10.31M 19.32M 19.4M 136M 52.49M 673M 51.81M 50.66M 2.16B
Net income	845K 8.81K 7.68K 7.25K 6.59K 12.34K 12.39K 86.87K 33.52K 430K 33.09K 32.35K 1.38M	25.57M 266K 232K 219K 199K 373K 375K 2.63M 1.01M 13M 1M 979K 41.82M
Net Debt	-6.79M -70.72K -61.67K -58.23K -52.88K -99.07K -99.49K -698K -269K -3.45M -266K -260K -11.1M	-29.59M -308K -269K -254K -231K -432K -434K -3.04M -1.17M -15.04M -1.16M -1.13M -48.4M